Inviting adolescents aged 12-17 for covid-19 vaccination: the need for patience
BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n2172 (Published 09 September 2021) Cite this as: BMJ 2021;374:n2172- Peter A M de Beer, specialist physician and adviser in global health and tropical medicine1,
- Koenraad Van den Abbeele, consultant physician2
- 1Medical Services for the Tropics/Dr de Beer Travel Clinic, Maastricht, Netherlands
- 2Department of Medicine, Wexham Park Hospital, Frimley Health NHS Foundation Trust, UK
- mstropics{at}planet.nl
The UK shows restraint in rolling out covid-19 vaccination for adolescents by reserving it for vulnerable children.1 We commend such prudence.2
The European Medicines Agency (EMA) recently accepted the Pfizer-BioNTech and Moderna covid-19 vaccines for use from 12 years old. Expected direct benefits are reductions in multisystem inflammatory syndrome in children and long covid; indirect benefits are less virus circulation and herd immunity because too many adults are refusing. EMA is reviewing vaccine side effects such as myocarditis and pericarditis.
The Dutch Health …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.